Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.43 USD | +0.78% | -1.83% | +3.71% |
Apr. 17 | Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating | MT |
Apr. 05 | Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.71% | 1.5B | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.72% | 22.2B | |
-16.53% | 21.23B | |
-9.05% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- ARDX Stock
- News Ardelyx, Inc.
- Ardelyx : Says Tenapanor Demonstrated Therapeutic Potential in Hyperphosphatemia Study - Shares Rise Pre-Bell